

Date 28 August 2026
Your Ref
Our Ref 11745

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 1st April 2026 and the end of June 2026, or latest 3-months for which data are available?
 - 1.1 Niraparib (Zejula)
 - 1.2 Rucaparib (Rubraca)
 - 1.3 Olaparib (Lynparza)
 - 1.4 Cemiplimab (Libtayo)
 - 1.5 Mirvetuximab soravtansine (Elahere)

Answer:

1.	12
2.	0
3.	22
4.	11
5.	5 or fewer

Question:

2. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
 - 2.1 Olaparib for all ovarian, fallopian tube or primary peritoneal cancers
 - 2.2 Olaparib + bevacizumab = 2.3 Olaparib monotherapy
 - 2.4 Bevacizumab or all ovarian, fallopian tube or primary peritoneal cancers
 - 2.5 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin
 - 2.6 Bevacizumab monotherapy

Answer:

1.	14
----	----

2.	5 or fewer
3.	13
4.	23
5.	5 or fewer
6.	13

Question:

3. How many patients were treated with rucaparib (Rubraca) for the following indications in the 3 months between 1st April 2026 to the end of June 2026 or latest 3-months for which data are available?
- 3.1 1L advanced ovarian cancer in response to 1L platinum chemotherapy (TA1055)
- 3.2 Relapsed platinum-sensitive ovarian cancer (TA1007)

Answer:

1.	Data unavailable, requires linkage
2.	Data unavailable, requires linkage

Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients and prescribing over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

4. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines in the 3 months between 1st April 2025 to the end of June 2026, or latest 3-months for which data are available?
- 4.1 Dostarlimab (Jemperli)
- 4.2 Pembrolizumab (Keytruda)
- 4.3 Lenvatinib (Lenvima)
- 4.4 Durvalumab (Imfinzi)

Answer:

1.	15
2.	15
3.	8
4.	5 or fewer

Question:

5. How many patients were treated for Endometrial Cancer (C54.1), with the following medicines as monotherapy or in combination, in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
- 5.1 Dostarlimab monotherapy
 - 5.2 Dostarlimab in combination with Chemotherapy
 - 5.3 Pembrolizumab monotherapy
 - 5.4 Pembrolizumab + Lenvatinib in combination
 - 5.5 Pembrolizumab in combination with Chemotherapy
 - 5.6 Durvalumab with Carboplatin and Paclitaxel
 - 5.7 Durvalumab monotherapy
 - 5.8 Durvalumab + Olaparib combination

Answer:

1.	11
2.	5 or fewer
3.	7
4.	0
5.	0
6.	0
7.	0
8.	0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

6. How many patients with Endometrial Cancer (C54.1) received the following treatments by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available?
- 6.1 Dostarlimab + Carboplatin + Paclitaxel
 - 6.2 Pembrolizumab + Carboplatin + Paclitaxel
 - 6.3 Pembrolizumab + Lenvatinib
 - 6.4 Dostarlimab as monotherapy at cycle 1
 - 6.5 Dostarlimab as monotherapy maintenance (cycle 7+)
 - 6.6 Pembrolizumab as monotherapy at cycle 1
 - 6.7 Pembrolizumab as monotherapy maintenance (cycle 7+)

Answer:

1.	Data unavailable, requires linkage
2.	Data unavailable, requires linkage
3.	Data unavailable, requires linkage
4.	Data unavailable, requires linkage
5.	Data unavailable, requires linkage
6.	Data unavailable, requires linkage
7.	Data unavailable, requires linkage

Question:

7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
- 7.1 Cutaneous Squamous Cell Carcinoma
- 7.2 Basal Cell Carcinoma
- 7.3 Non-small Cell Lung Cancer
- 7.4 Cervical Cancer

Answer:

1.	11
2.	0
3.	0
4.	0

Question:

8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
- 8.1 Curative
- 8.2 Palliative

Answer:

1.	0
2.	11

Question:

9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available?
- 9.1 Adjuvant

Answer:

1.	0
----	---

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive